ArticleInfection and immunity2003
Characterization of antibody responses to Wolbachia surface protein in humans with lymphatic filariasis.
Article in Infection and immunity, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 56 citations in OpenAlex.
- Multiplex bead assay for serum samples from children in Haiti enrolled in a drug study for the treatment of lymphatic filariasis.The American journal of tropical medicine and hygiene · 2011Trial
- Current perspectives in the epidemiology and control of lymphatic filariasis.Clinical microbiology reviews · 2025Review
- Interaction between Wolbachia pipientis and Leishmania infantum in heartworm infected dogs.Parasites & vectors · 2023Article
- Transient Introgression ofPathogens (Basel, Switzerland) · 2022Article
- Parasite-bacteria interrelationship.Parasitology research · 2020Review
- Review of Dancing Parasites in Lymphatic Filariasis.Ultrasound international open · 2019Review
- Signatures of balancing selection in toll-like receptor (TLRs) genes - novel insights from a free-living rodent.Scientific reports · 2018Article
- Analysis of gene expression from the Wolbachia genome of a filarial nematode supports both metabolic and defensive roles within the symbiosis.Genome research · 2012Article
- The NIH-NIAID Filariasis Research Reagent Resource Center.PLoS neglected tropical diseases · 2011Review
- Tissue and stage-specific distribution of Wolbachia in Brugia malayi.PLoS neglected tropical diseases · 2011Article
- Association between Toll-like receptor 2 (TLR2) polymorphisms and asymptomatic bancroftian filariasis.Parasitology research · 2010Article
- Wolbachia lipoprotein stimulates innate and adaptive immunity through Toll-like receptors 2 and 6 to induce disease manifestations of filariasis.The Journal of biological chemistry · 2009Article
- Detection of Wolbachia bacteria in multiple organs and feces of the triatomine insect Rhodnius pallescens (Hemiptera, Reduviidae).Applied and environmental microbiology · 2009Article
- Activation and regulation of toll-like receptors (TLRs) by helminth parasites.Immunologic research · 2009Review
- Of mice, cattle, and humans: the immunology and treatment of river blindness.PLoS neglected tropical diseases · 2008Review
- Immunopathology of Dirofilaria immitis infection.Veterinary research communications · 2007Review
- Proinflammatory cytokine gene expression by murine macrophages in response to Brugia malayi Wolbachia surface protein.Mediators of inflammation · 2007Article
- Emerging infectious determinants of chronic diseases.Emerging infectious diseases · 2006Article
- Wolbachia- and Onchocerca volvulus-induced keratitis (river blindness) is dependent on myeloid differentiation factor 88.Infection and immunity · 2006Article
- Protective immunity to the larval stages of onchocerca volvulus is dependent on Toll-like receptor 4.Infection and immunity · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Symbiotic Wolbachia organisms of filarial nematodes have received much attention as possible chemotherapy targets and disease-causing organisms. In order to further investigate the association between anti-Wolbachia immune responses and chronic filarial disease in humans, antibody responses to Wolbachia surface protein (WSP) were assayed in serum samples collected from 232 individuals living in Leogane, Haiti, an area where Wuchereria bancrofti infection is endemic, and from 67 North Americans with no history of lymphatic filariasis. As opposed to antifilarial antibody responses, which were largely influenced by the patient's infection status, the prevalence and levels of anti-WSP immunoglobulin G (IgG) antibodies among individuals with lymphedema or hydrocele were significantly greater than those in gender- and infection-matched individuals without disease. In at least one case, the anti-WSP IgG response was coincident with the onset of lymphedema development, and among anti-WSP-positive women with lymphedema, anti-WSP IgG levels were negatively correlated with the duration of lymphedema. The presence of anti-WSP IgG was also associated with the severity of inguinal adenopathy among men with hydrocele. In addition to the presence of anti-WSP antibodies among Haitians, 15 of 67 (22%) serum samples collected from individuals from North America, where filariasis is not endemic, were also positive for anti-WSP antibodies. In comparison to those from Haitians, anti-WSP antibodies from North Americans primarily recognized a distinct region of WSP located within the highly conserved second transmembrane domain. The results of this study demonstrate that anti-WSP antibody responses are associated with the presence of chronic filarial morbidity and not filarial infection status in humans and suggest that WSP should be further studied as a potential trigger for the development of filarial disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.